

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM833757

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
NEUROS MEDICAL, INC.		08/10/2023	Corporation: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Trinity Capital Inc.		
<b>Street Address:</b>	1 N 1st Street, Floor 3		
<b>City:</b>	Phoenix		
<b>State/Country:</b>	ARIZONA		
<b>Postal Code:</b>	85004		
<b>Entity Type:</b>	Corporation: MARYLAND		
<b>PROPERTY NUMBERS Total: 4</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	4362014	NEUROS MEDICAL	
<b>Registration Number:</b>	4368960	N NEUROS MEDICAL	
<b>Registration Number:</b>	4452008	ALTIUS	
<b>Serial Number:</b>	97657556	NEUROS	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	2023704750		
<b>Email:</b>	ipteam@coagencyglobal.com		
<b>Correspondent Name:</b>	Rodney Boulware		
<b>Address Line 1:</b>	1025 Connecticut Ave NW, Suite 712		
<b>Address Line 2:</b>	COGENCY GLOBAL INC.		
<b>Address Line 4:</b>	Washington, D.C. 20036		
<b>ATTORNEY DOCKET NUMBER:</b>	2098405 TM		
<b>NAME OF SUBMITTER:</b>	Yvette Stohler		
<b>SIGNATURE:</b>	/Yvette Stohler/		
<b>DATE SIGNED:</b>	08/22/2023		
<b>Total Attachments: 8</b>			

OP \$115.00 4362014

source=Trinity-Neuros IPSA 8-10-23#page1.tif  
source=Trinity-Neuros IPSA 8-10-23#page2.tif  
source=Trinity-Neuros IPSA 8-10-23#page3.tif  
source=Trinity-Neuros IPSA 8-10-23#page4.tif  
source=Trinity-Neuros IPSA 8-10-23#page5.tif  
source=Trinity-Neuros IPSA 8-10-23#page6.tif  
source=Trinity-Neuros IPSA 8-10-23#page7.tif  
source=Trinity-Neuros IPSA 8-10-23#page8.tif

## INTELLECTUAL PROPERTY SECURITY AGREEMENT

**THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT** ("Agreement") dated as of August 10, 2023, is made by NEUROS MEDICAL, INC., a Delaware corporation (the "Grantor") in favor of TRINITY CAPITAL INC., a Maryland corporation, as administrative agent and collateral agent for the Lenders ("Administrative Agent").

### RECITALS

A. Grantor has entered into a Loan and Security Agreement with the Lenders party thereto and the Administrative Agent, dated as of the date hereof (as amended, restated, or otherwise modified from time to time, the "Loan Agreement"). All capitalized terms used but not defined herein shall have the respective meanings given to them in the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Administrative Agent for its benefit a security interest in all of Grantor's right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, the parties hereto agree as follows:

### AGREEMENT

1. Grant of Security Interest. To secure its obligations under the Loan Agreement, Grantor grants and pledges to Administrative Agent, for the benefit of the Lenders, a security interest in all of Grantor's right, title and interest in, to and under its intellectual property (all of which shall collectively be called the "Intellectual Property Collateral"), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the "Copyrights");

(b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions, re-examination certificates, utility models, and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the "Patents");

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the "Trademarks");

(f) All mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on Exhibit D attached hereto (collectively, the "Mask Works");

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) All amendments, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

(j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

Notwithstanding the foregoing, the Intellectual Property Collateral does not include any of the following: (a) rights held under a license, state or local franchise, charter or authorization, or other agreement that are not assignable by their terms without the consent of the licensor or other issuer of such franchise, charter, or authorization or counterparty to such agreement thereof (but only to the extent such restriction on assignment is enforceable under applicable law); and (b) any ~~intent-to-use~~ trademarks but only to the extent and solely during such period that granting a security interest in the "intent-to-use" trademarks would be contrary to applicable law or may interfere with Grantor's rights to obtain and maintain such trademarks; provided that, after such period, Grantor acknowledges that such interest in such trademark application or trademark shall be subject to a security interest in favor of Administrative Agent and shall be included in the Intellectual Property Collateral.

2. Recordation. Grantor authorizes the Commissioner for Patents, the Commissioner for Trademarks and the Register of Copyrights and any other government officials to record and register this Agreement upon request by Administrative Agent.

Grantor hereby authorizes Administrative Agent to (a) modify this Agreement unilaterally by amending the exhibits to this Agreement to include any Intellectual Property Collateral which Grantor obtains subsequent to the date of this Agreement and (b) file a duplicate original of this Agreement containing amended exhibits reflecting such new Intellectual Property Collateral.

3. Loan Documents. This Agreement has been entered into pursuant to and in conjunction with the Loan Agreement, which is hereby incorporated by reference. The provisions of the Loan Agreement shall supersede and control over any conflicting or inconsistent provision herein. The rights and remedies of Administrative Agent with respect to the Intellectual Property Collateral are as provided by the Loan Agreement and related documents, and nothing in this Agreement shall be deemed to limit such rights and remedies.

4. Execution in Counterparts. This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument. Delivery of an executed counterpart of a signature page of this Agreement by facsimile, portable document format (.pdf) or other electronic transmission will be as effective as delivery of a manually executed counterpart hereof.

5. Successors and Assigns. The provisions of this Agreement shall inure to the benefit of the parties hereto and their respective successors and assigns. Grantor shall not assign its obligations under this Agreement without Administrative Agent's express prior written consent, and any such attempted assignment shall be void and of no effect. Administrative Agent may assign, transfer, or endorse its rights hereunder pursuant to the terms of the Loan Agreement without prior notice to Grantor, and all of such rights shall inure to the benefit of Administrative Agent's successors and assigns.

6. Governing Law. This Agreement has been negotiated and delivered to Administrative Agent in the State of California, and shall have been accepted by Administrative Agent in the State of California. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.


***[Balance of Page Intentionally Left Blank.]***

COPY VIEW

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to  
be duly executed as of the day and year first above written.


**GRANTOR:**

**NEUROS MEDICAL, INC.,**  
a Delaware corporation

DocuSigned by:  
  
By: \_\_\_\_\_  
Name: Thomas C. Wilder, III  
Title: Chief Executive Officer

**ADMINISTRATIVE AGENT:**

**TRINITY CAPITAL INC.,**  
a Maryland corporation

DocuSigned by:  
  
By: \_\_\_\_\_  
Name: Sarah Stanton  
Title: General Counsel and Chief Compliance  
Officer

COPY  
VIEW

**EXHIBIT A**

**COPYRIGHTS**

**None.**

**COPY VIEW**

**EXHIBIT B****PATENTS**

TITLE	APLN NO	DATE FILED	PUBLICATION NUMBER	PUBLICATION DATE	PATENT NUMBER
HIGH-FREQUENCY ELECTRICAL NERVE BLOCK OF PERIPHERAL PAIN	13/474,926	May 18, 2012	US-2012-0296389-A1	Nov 22, 2012	8,731,676
HIGH-FREQUENCY ELECTRICAL NERVE BLOCK	14/276,200	May 13, 2014	US-2014-0249597-A1	Sep 4, 2014	8,983,612
NERVE CUFF ELECTRODE FOR NEUROMODULATION IN LARGE HUMAN NERVE TRUNKS	17/850,843	Jun 27, 2022	US-2022-0339446-A1	Oct 27, 2022	
HIGH-FREQUENCY ELECTRICAL NERVE BLOCK	14/656,256	Mar 12, 2015	US-2015-0182749-A1	Jul 2, 2015	9,295,841
NERVE CUFF ELECTRODE FOR NEUROMODULATION IN LARGE HUMAN NERVE TRUNKS	17/009,541	Sep 1, 2020	US-2020-0391032-A1	Dec 17, 2020	11,413,458
NERVE CUFF ELECTRODE FOR NEUROMODULATION IN LARGE HUMAN NERVE TRUNKS	15/510,824	Sep 12, 2014	US-2017-0246453-A1	Aug 31, 2017	10,758,723
APPARATUSES AND METHODS FOR ADJUSTING A THERAPEUTIC ELECTRICAL DOSE	17/265,532	Aug 20, 2019	US-2021-0220642-A1	Jul 22, 2021	
NERVE CUFF DEPLOYMENT DEVICES	17/444,876	Aug 11, 2021	US-2021-0370054-A1	Dec 2, 2021	
NERVE CUFF DEPLOYMENT DEVICES	16/954,049	Dec 13, 2018	US-2021-0008366-A1	Jan 14, 2021	11,116,965
APPARATUSES AND METHODS FOR SETTING AN ELECTRICAL DOSE	16/379,053	Apr 9, 2019	US-2019-0308020-A1	Oct 10, 2019	11,213,682
APPARATUSES AND METHODS FOR SETTING AN ELECTRICAL DOSE	17/455,392	Nov 17, 2021	US-2022-0072310-A1	Mar 10, 2022	
SYSTEM AND METHOD FOR QUANTIFYING QUALITATIVE PATIENT-REPORTED DATA SETS	17/174,014	Feb 11, 2021	US-2021-0244952-A1	Aug 12, 2021	
APPARATUSES AND METHODS FOR SETTING AN ELECTRICAL DOSE	63/417,646	Oct 19, 2022			
APPARATUSES AND METHODS FOR SETTING AN ELECTRICAL DOSE	18/346,499	Jul 3, 2023			



**EXHIBIT C****TRADEMARKS**

<b>TITLE</b>	<b>APLN NO</b>	<b>DATE FILED</b>	<b>TMK PUBLICATION DATE</b>	<b>TMK REG NO</b>	<b>TMK REGISTRATION DATE</b>
NEUROS MEDICAL	85/485,689	Dec 2, 2011	May 22, 2012	4362014	Jul 2, 2013
N NEUROS MEDICAL & DESIGN	85/178,939	Nov 17, 2010	Apr 26, 2011	4368960	Jul 16, 2013
ALTIUS	85/616,592	May 4, 2012	Oct 16, 2012	4452008	Dec 17, 2013
NEUROS	97657556	Nov 1, 2022			

COPY VIEW

**EXHIBIT D**

**MASK WORKS**

**None.**

**COPY VIEW**